Chongqing Precision Biotech Co., Ltd.

Cn
En

INNOVATION FOR HEALTH

BUILD A GLOBAL AND INNOVATIVE BIOPHARMACEUTICAL ENTERPRISE

Production technology platform

Basic research and development platform

Planning to build Chongqing Regional Cell Preparation Center

ABOUT US

18000_㎡

IND and NDA Platforms For Cell-based Drug

10₊

Pipeline

4

Class I New Drugs

10

Indication

47

Patents

200₊

R&D Elite

CORPORATE
CULTURE

MANAGEMENT
TEAM

PIPELINE

R&D PLATFORM

CORE TECHNOLOGY

MANUFACTURING

NEWS & INFORMATION

Professor Qian Cheng Recognized Among the World’s Leading Scientists in the 2026 Global Scholar Academic Influence Ranking

The 2026 Global Scholar Academic Influence Ranking has been released,Professor Qian was ranked No. 71,558 worldwide, reflecting his contributions to scientific research and innovation in gene and cell therapy.

Chongqing Precision Biotech Recognized for Innovation at BIONNOVA Forum；Prof. Qian Cheng Highlights Advances in In Vivo CAR-T

April 22–23, 2026 — Chongqing Precision Biotech Co., Ltd. was recognized with the “Most Innovative Pharmaceutical Company” award at the 7th BIONNOVA Biopharmaceutical Innovators Forum, held at Zha...

Chongqing Precision Biotech Announces Nature Cancer Publication of Phase 1 Data for Hypoxia-Responsive CEA-Targeted CAR-T Therapy in Solid Tumors

February 27, 2026 — Chongqing Precision Biotech Co., Ltd. announced that results from a Phase 1 clinical study of its internally developed hypoxia-responsive CEA-targeted CAR-T cell therapy (PC13) ha...

CR/MRD-Negative Remission at Day 28: Initial Efficacy Results for First Patient Treated with Puzolcabtagene Autoleucel Injection in China

Recent advances in multi-agent chemotherapy have improved outcomes for pediatric and adolescent patients with B-cell acute lymphoblastic leukemia (B-ALL). However, patients with relapsed or refractory...

FOLLOW US ON WECHAT

© Copyright 2016-2025 重庆精准生物技术有限公司 All Rights Reserved

渝ICP备16003030号-1

渝公网安备 50010702505019号

渝网药械信备字[2026]000022号 Design By:zhiing